InvestSMART

Biome Australia Limited (ASX:BIO)

ALERT: Price-sensitive ASX Announcement for BIO
Current share price for BIO : $0.260 -0.155 (-37.35%)+
Announcement
Release
5 Jan 2026 8:37AM
Price at Release
$0.415
Full Release
download
Summary
Biome Australia Limited, an Australian company focused on developing and marketing evidence-based live biotherapeutics (probiotics) and complementary medicines, reported a strong trading update for Q2 FY26. The company achieved a quarterly revenue of $6.48 million, marking a 40.9% increase compared to the same period in the previous year and a 9.1% increase from Q1 FY26. For the first half of FY26, revenue reached $12.42 million, a 40.2% growth over the previous year. Despite seasonal challenges, the demand for Biome's clinically-proven probiotic products remained robust. The company's products, which include the Activated Probiotics® range, are supported by clinical research and are aimed at improving various health conditions. Biome Australia is committed to educating health professionals on the systemic health effects of gut microbiota.
Key Points
  • Q2 FY26 revenue was $6.48 million, a 40.9% increase over Q2 FY25.
  • H1 FY26 revenue reached $12.42 million, a 40.2% increase from H1 FY25.
  • Revenue growth was achieved despite seasonal trading challenges.
  • Biome focuses on probiotics and complementary medicines supported by clinical research.
  • The company aims to improve health outcomes and make products accessible.
  • Activated Probiotics® is Biome's flagship range.
  • Biome collaborates with leading microbiome research organizations.
  • The company emphasizes practitioner-only distribution and education.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.